Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Clinical trial NCT01450319 · COMPLETED
Trial details
- NCT number
- NCT01450319
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-12-01
- Primary completion
- 2014-12-01
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.